7JS.F Diagnostyka S.A.
- Market cap
- EUR 1.15B
- P/E
- 19.1x
- P/B
- 9.78x
- ROE
- 54.9%
- Dividend yield
- 3.08%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7JS.F undervalued?
Graham number7JS.F trades 188.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Diagnostyka S.A. fundamental analysis
No fundamental analysis for Diagnostyka S.A. yet.
Diagnostyka S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Diagnostyka S.A.
Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It also offers specialized research in the field of microbiology, autoimmunity, toxicology, and molecular biology, as well as human genome research, histopathological examinations, immunohistochemical tests, cytological tests, and cytogenetic tests. The company provides se…
Full company profileDiagnostyka S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Diagnostyka S.A. annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.84B | 1.44B | 1.59B | 1.95B | 2.41B | 2.71B |
| Gross Profit | 1.30B | 936M | 1.03B | 1.53B | 1.91B | 2.13B |
| Operating Income | 688M | 252M | 233M | 337M | 384M | 438M |
| EBITDA | - | 381M | 375M | 510M | 588M | 672M |
| Net Income | 558M | 167M | 123M | 223M | 252M | 280M |
| EPS | 17 | 4.96 | 3.66 | 6.62 | 7.45 | 8.29 |
| Balance Sheet | ||||||
| Total Assets | 1.26B | 1.20B | 1.40B | 1.72B | 2.07B | 2.23B |
| Total Liabilities | 819M | 878M | 1.06B | 1.28B | 1.52B | 1.70B |
| Shareholders' Equity | 438M | 313M | 325M | 419M | 528M | 510M |
| Cash & Short-term Investments | 164M | 91.0M | 94.9M | 40.5M | 18.4M | 17.6M |
| Cash Flow | ||||||
| Operating Cash Flow | 739M | 284M | 336M | 415M | 552M | 526M |
| Capital Expenditure | 132M | 89.4M | 81.3M | 133M | 205M | 134M |
| Free Cash Flow | 607M | 195M | 255M | 283M | 347M | 392M |
| Ratios | ||||||
| ROE | 127.5% | 53.6% | 38.0% | 53.3% | 47.6% | 54.9% |
| ROA | 44.2% | 14.0% | 8.8% | 13.0% | 12.2% | 12.5% |
| Net Profit Margin | 30.3% | 11.7% | 7.8% | 11.5% | 10.4% | 10.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Diagnostyka S.A. dividends
- Dividend yield
- 3.08%
- Forward dividend
- 1.03 EUR
- Payout ratio
- 44.4%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | PLN 112M | 3.31 | 44.4% |
| 2024 | PLN 106M | 3.13 | 47.3% |
| 2023 | PLN 112M | 3.32 | 90.8% |
| 2022 | PLN 294M | 8.72 | 175.8% |
| 2021 | PLN 413M | 12 | 74.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Diagnostyka S.A.
- Insiders 47.20%
- Institutions 16.82%
- Public & others 35.98%
- Shares outstanding 33.8M
- Free float 16.4M
Diagnostyka S.A. company profile
- Company name
- Diagnostyka S.A.
- Ticker
- 7JS.F
- ISIN
- PLDGNST00012
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 8,645
- Fiscal year end
- December
- Address
- Ul. Prof. Michala Zyczkowskiego 16, Kraków, Poland, 31-864
- Phone
- 48 12 295 0100
- Website
- diag.pl
About Diagnostyka S.A.
Diagnostyka S.A. provides diagnostic services in Poland. The company operates as a medical laboratory, which offers services, such as ultrasound, X-ray, computed tomography, and magnetic resonance imaging. It also offers specialized research in the field of microbiology, autoimmunity, toxicology, and molecular biology, as well as human genome research, histopathological examinations, immunohistochemical tests, cytological tests, and cytogenetic tests. The company provides services to individual clients, and public and private entities. Diagnostyka S.A. was founded in 1998 and is headquartered in Kraków, Poland.
Diagnostyka S.A. management
4- Mr. Jakub SwadzbaCo-Founder, CEO & President of the Management Board
- Mr. Jaromir PelczarskiVice-President of the Management Board & Chief Transformation Officer
- Ms. Marta Rogalska-KupiecVice-President of the Management Board & Chief Operating Officer
- Mr. Dariusz ZowczakChief Sales Officer & Vice-President of the Management Board